secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001641172-25-006548
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Abeona's ZEVASKYN, first cell-based gene therapy for RDEB
----------------------------------------------------------------------

- 81% of ZEVASKYN-treated wounds achieved ≥50% healing at 6 months vs 16% control (P<0.0001) in Phase 3 VIITAL study.
- Rare Pediatric Disease Priority Review Voucher granted; company plans to monetize the PRV.
- ZEVASKYN available through Qualified Treatment Centers starting 3Q 2025; Abeona Assist support program launched.
- CEO cites pivotal moment for RDEB community; single surgical application aims for long-term wound healing and pain reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/0001641172-25-006548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-006548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer